Efficacy and Safety of Crisugabalin with Acetyl-Levo-Carnitine in Chinese Patients with Diabetic Peripheral Neuropathic Pain-A Multicentre, Randomized, Open-Label, Positive-Controlled, Parallel-Group, Phase 2 Trial

被引：0
|
作者：
Jiang, Hongwei
Fu, Liujun
Xu, Na
Shang, Junjie
Yang, Qiuwei
机构：
来源：
DIABETES | 2024年 / 73卷
关键词：
D O I：
10.2337/db24-868-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
868-P
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Efficacy and Safety of Dutasteride in Chinese Adults with Symptomatic Benign Prostatic Hyperplasia A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study with an Open-Label Extension
    Na, Yanqun
    Ye, Zhangqun
    Zhang, Shanzhong
    CLINICAL DRUG INVESTIGATION, 2012, 32 (01) : 29 - 39
  • [22] Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202) : a multicentre, randomised, parallel-group, open-label, phase 2 trial
    Wedemeyer, Heiner
    Schoeneweis, Katrin
    Bogomolov, Pavel
    Blank, Antje
    Voronkova, Natalia
    Stepanova, Tatiana
    Sagalova, Olga
    Chulanov, Vladimir
    Osipenko, Marina
    Morozov, Viacheslav
    Geyvandova, Natalia
    Sleptsova, Snezhana
    Bakulin, Igor G.
    Khaertynova, Ilsiyar
    Rusanova, Marina
    Pathil, Anita
    Merle, Uta
    Bremer, Birgit
    Allweiss, Lena
    Lempp, Florian A.
    Port, Kerstin
    Haag, Mathias
    Schwab, Matthias
    Wiesch, Julian Schulze zur
    Cornberg, Markus
    Haefeli, Walter E.
    Dandri, Maura
    Alexandrov, Alexander
    Urban, Stephan
    LANCET INFECTIOUS DISEASES, 2023, 23 (01): : 117 - 129
  • [23] Safety and efficacy of tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in japan (SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial
    Kadowaki, Takashi
    Chin, Rina
    Ozeki, Akichika
    Imaoka, Takeshi
    Ogawa, Yoshihiro
    LANCET DIABETES & ENDOCRINOLOGY, 2022, 10 (09): : 634 - 644
  • [24] Efficacy and safety of leuprorelin acetate 6-month depot in prostate cancer patients: a Phase III, randomized, open-label, parallel-group, comparative study in Japan
    Suzuki, Kazuhiro
    Namiki, Mikio
    Fujimoto, Tsukasa
    Takabayashi, Nobuyoshi
    Kudou, Kentarou
    Akaza, Hideyuki
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2015, 45 (12) : 1168 - 1174
  • [25] Efficacy of a Digital Diabetes Logbook for People With Type 1, Type 2, and Gestational Diabetes: Results From a Multicenter, Open-Label, Parallel-Group, Randomized Controlled Trial
    Ehrmann, Dominic
    Hermanns, Norbert
    Finke-Groene, Katharina
    Roos, Timm
    Kober, Johanna
    Schaefer, Vanessa
    Krichbaum, Michael
    Haak, Thomas
    Ziegler, Ralph
    Heinemann, Lutz
    Rieger, Cosima
    Bingol, Ezgi
    Kulzer, Bernhard
    Silbermann, Stephan
    JOURNAL OF DIABETES SCIENCE AND TECHNOLOGY, 2024,
  • [26] The Efficacy and Safety of Abelmoschus manihot for Reduction of Microalbuminuria in Patients with Type 2 Diabetes and Diabetic Nephropathy-A Multicenter, Randomized, Open-Label, Parallel-Controlled Clinical Trial
    Yin, Jun
    Chen, Si
    Wei, Li
    Jia, Weiping
    DIABETES, 2023, 72
  • [27] Itolizumab in combination with methotrexate modulates active rheumatoid arthritis: safety and efficacy from a phase 2, randomized, open-label, parallel-group, dose-ranging study
    Chopra, Arvind
    Chandrashekara, S.
    Iyer, Rajgopalan
    Rajasekhar, Liza
    Shetty, Naresh
    Veeravalli, Sarathchandra Mouli
    Ghosh, Alakendu
    Merchant, Mrugank
    Oak, Jyotsna
    Londhey, Vikram
    Barve, Abhijit
    Ramakrishnan, M. S.
    Montero, Enrique
    CLINICAL RHEUMATOLOGY, 2016, 35 (04) : 1059 - 1064
  • [28] Itolizumab in combination with methotrexate modulates active rheumatoid arthritis: safety and efficacy from a phase 2, randomized, open-label, parallel-group, dose-ranging study
    Arvind Chopra
    S. Chandrashekara
    Rajgopalan Iyer
    Liza Rajasekhar
    Naresh Shetty
    Sarathchandra Mouli Veeravalli
    Alakendu Ghosh
    Mrugank Merchant
    Jyotsna Oak
    Vikram Londhey
    Abhijit Barve
    M. S. Ramakrishnan
    Enrique Montero
    Clinical Rheumatology, 2016, 35 : 1059 - 1064
  • [29] Efficacy and safety of every-2-week darbepoetin alfa in patients with anemia of cancer: A controlled, randomized, open-label phase II trial
    Charu, Veena
    Belani, Chandra P.
    Gill, Ahmad N.
    Bhatt, Mukesh
    Tomita, Dianne
    Rossi, Greg
    Ben-Jacob, Ali
    ONCOLOGIST, 2007, 12 (06): : 727 - 737
  • [30] DAPagliflozin for the attenuation of albuminuria in Patients with hEaRt failure and type 2 diabetes (DAPPER study): a multicentre, randomised, open-label, parallel-group, standard treatment-controlled trial
    Yoshihara, Fumiki
    Imazu, Miki
    Sakuma, Ichiro
    Hiroi, Yukio
    Hara, Hisao
    Okazaki, Osamu
    Ishiguro, Chizuru
    Izumi, Chisato
    Noguchi, Teruo
    Shiraiwa, Toshihiko
    Nishioka, Norio
    Fujii, Kenshi
    Iwakura, Katsuomi
    Tomonaga, Osamu
    Kobayashi, Koichi
    Himi, Toshiharu
    Takihata, Masahiro
    Yumoto, Kazuhiko
    Takase, Hiroyuki
    Shimizu, Ikki
    Murakami, Tsutomu
    Wagatsuma, Kenji
    Sato, Katsuhiko
    Hiramatsu, Takeyuki
    Akabame, Satoshi
    Hata, Shiro
    Asakura, Masanori
    Kawabata, Takanori
    Omae, Katsuhiro
    Ito, Shin
    Kitakaze, Masafumi
    ECLINICALMEDICINE, 2023, 66
12345